Factbox: Court Challenges to Medicare Drug Price Negotiation Plan by Reuters

(Reuters) – Manufacturers of ten prescription drugs included in the U.S. Medicare price negotiation process have agreed to participate in discussions by the October 1 deadline. However, Novo Nordisk has initiated legal action to halt these negotiations. From June to late September, at least nine lawsuits were filed asserting that the legislation and mandated price reductions would infringe upon various amendments of the U.S. Constitution.

Here are some key details about the lawsuits:

| Company | Date | Location | Drugs mentioned |
|—————————|———-|——————————————|——————————————-|
| Merck & Co | June 6 | U.S. District Court for the District of Columbia | Diabetes drugs: Januvia, Janumet; Cancer treatment: Keytruda |
| U.S. Chamber of Commerce | June 9 | U.S. District Court for the Southern District of Ohio, Western Division | NA |
| Bristol Myers Squibb | June 16 | U.S. District Court for the District of New Jersey | Blood thinner: Eliquis; Cancer therapy: Opdivo |
| Johnson & Johnson | July 18 | U.S. District Court for the District of New Jersey | Blood thinner: Xarelto |
| Pharmaceutical Research and Manufacturers of America | June 21 | U.S. District Court for the Western District of Texas, Austin Division | NA |
| Boehringer Ingelheim | Aug 18 | U.S. District Court for the District of Connecticut | Diabetes drug: Jardiance |
| AstraZeneca | Aug 25 | U.S. District Court for the District of Delaware | Cancer drug: Lynparza; Blood disorder treatment: Soliris |
| Novartis | Sept 1 | U.S. District Court for the District of New Jersey | Heart-failure drug: Entresto |
| Novo Nordisk | Sept 29 | U.S. District Court for the District of New Jersey | Insulin: Aspart |

These lawsuits highlight the ongoing disputes over pricing regulations in the pharmaceutical industry and their implications for both manufacturers and consumers.